The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Recent News

FDA Approves Pembrolizumab Plus Axitinib in Advanced Kidney Cancer
Does Bladder-Sparing Therapy Plus Vinorelbine Improve Survival in Cisplatin-Ineligible Patients?
Accelerated FDA Approval Granted to Erdafitinib for Metastatic Urothelial Carcinoma
AACR 2019: Can B Cells Predict Response to Immunotherapy in Renal Cell Carcinoma?
EAU Congress 2019: Early Menopause in Smokers and Bladder Cancer Risk
Tumor-Lysis Syndrome in Patients With Genitourinary Cancers
Nivolumab in Metastatic Kidney Cancer in ‘Real-World Setting’
Predicting Outcomes With Lung Immune Prognostic Index
Postoperative Chemotherapy Plus Radiotherapy for Locally Advanced Bladder Cancer
2019 GU Symposium: Subgroup Analysis of Avelumab + Axitinib in JAVELIN Renal 101 Trial
2019 GU Symposium: Tivozanib Versus Sorafenib in Advanced Renal Cell Carcinoma
Priority Review Granted to Pembrolizumab Combination in First-Line Therapy for Advanced Kidney Cancer
FDA Accepts for Priority Review Avelumab and Axitinib Combination for Advanced Kidney Cancer
2019 GU Symposium: Cabozantinib vs. Everolimus in METEOR Trial of Kidney Cancer
2019 GU Symposium: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer
Risk Factors for Renal Cell Carcinoma Related to Obesity
Computer-Designed Protein Mimics Interleukin-2 With Less Toxicity
Kidney Cancer and Rare Genetic Tumor Syndrome
Sorafenib Versus Other Targeted Agents in Metastatic Renal Cell Carcinoma
Northwestern Medicine Receives $10 Million Gift to Create Urologic Cancer Institute
TKIs After Immunotherapy Failure in Metastatic Renal Cell Carcinoma
Predicting Prognosis for Patients With Metastatic Papillary Renal Cell Carcinoma
Clinical Trial of Personalized Vaccine in Kidney Cancer Commences
Validated Risk Model Integrates Molecular Features in Advanced Renal Cancer
Annexin A1 Expression in Renal Cell Carcinoma
Identifying Optimal Dose of Cyclophosphamide With Everolimus in Metastatic Kidney Cancer
Pegilodecakin Plus Anti–PD-1 Therapy for Renal Cell Carcinoma
ATLAS Trial: Axitinib in Patients at High Risk of Recurrence of Kidney Cancer
Exploring the Mechanism of MTAP Regulation in Renal Cell Carcinoma
Kidney Week 2018: Does Diabetes Increase the Risk for Renal Tumorigenesis?
Breakthrough Therapy Designation Granted by FDA to UGN-101 in Urothelial Cancer
ESMO 2018: Cabozantinib in PD-L1–Unselected Patients With Metastatic Kidney Cancer
ESMO 2018: In Kidney Cancer, Response to Treatment Varies With Gene Expression
ASTRO 2018: Stereotactic Ablative Radiotherapy for Patients With One Kidney
ESMO 2018: Novel First-Line Combination Therapy for Advanced Kidney Cancer
Kidney Week 2018: Shedding Light on Origin of Papillary Kidney Cancer
ASTRO 2018: Toxicity of Stereotactic Body Radiation Therapy in Primary Kidney Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.